Exact Sciences Raises Their 2024 Adjusted EBITDA Guidance After Strong Q2 Performance, Achieving Record Profitability; Expanding Margins While Reinvesting In Growth, Aiming For Over 20% EBITDA Margins By 2027
Exact Sciences Raises Their 2024 Adjusted EBITDA Guidance After Strong Q2 Performance, Achieving Record Profitability; Expanding Margins While Reinvesting In Growth, Aiming For Over 20% EBITDA Margins By 2027
精密科學在強勁的第二季表現之後提高了他們2024年的調整後息稅折舊及攤銷前利潤指引，實現了創紀錄的盈利能力；在重新投資增長的同時擴大利潤率，旨在在2027年實現超過20%的息稅折舊及攤銷前利潤率。
Exact Sciences Raises Their 2024 Adjusted EBITDA Guidance After Strong Q2 Performance, Achieving Record Profitability; Expanding Margins While Reinvesting In Growth, Aiming For Over 20% EBITDA Margins By 2027
在第二季度表現強勁之後，Exact Sciences上調了2024年調整後的息稅折舊攤銷前利潤預期，實現了創紀錄的盈利能力；擴大了利潤率，同時對增長進行了再投資，目標是到2027年實現超過20％的息稅折舊攤銷前利潤率
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。